Structure Therapeutics (GPCR) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

GPCR Structure Therapeutics

Watchlist

27.900
-3.580-11.37%

Close Dec 18 16:00 ET

27.210
-0.690-2.47%

Post 19:54 ET

1.60BMarket Cap-14.45P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Moomoo News18:32 ET · Ratings
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy From Piper Sandler
TipRanks16:55 ET · Ratings
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
BarronsDec 18 10:25 ET
Express News | Shares of Structure Therapeutics Fall 7.2%, Viking Therapeutics Fall 7.9%
ReutersDec 18 09:34 ET
Express News | Shares of Some Obesity Drug Developers Fall After Merck Signs up to $2 Bln Deal for Oral Obesity Drug
ReutersDec 18 09:33 ET
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Moomoo NewsDec 18 09:33 ET · Ratings

Comments

104266827

Sep 23 07:37

still uptrend..go buy target price $65

Share Your Profit/Loss

Jensen 108

Sep 13 11:34

this one so hard to achieve 10% above. profit taken first.

Share Your Profit/Loss

Jensen 108

Aug 13 09:44

$Structure Therapeutics (GPCR.US)$ hopefully the uptrend continues

Meltyy

Jul 17 22:40

Smid-cap obesity stocks hit by $RHHBY positive Ph1 data for oral GLP-1 obesity drug ⚠️

$ROCHE HOLDING AG (RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$

frankinglily

Jul 12 03:26

Is the diet pill market too profitable to lose?

Why do you think $Pfizer (PFE.US)$ decided to progress with Danuglipron? (Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA